you, thank everyone. good Susan, afternoon, and Well,
you XXXX ensure organization, in an as to beyond. is well and our know, positioned XXXX that, accelerated we're top deliver to growth As in priority
It's and we're with important straightforward to deliver resonates Since we've call, employees. continued areas: to a yet pain therapies and personally a non-opioid innovative compelling Pacira that me lives aligned in our patients. X the key make first, of refreshed clear last to mission now committed progress our mission transform to
well. principles patient at the science, Underpinning our and the that uphold the are keep center, our we mission X people every guiding follow day: treat
on all pain therapeutic defined growing need a of significant area high are innovation. and review adjacencies. we've Second, strategy long-term growth-oriented and are for portfolio plan poised comprehensive and that unmet markets These completed and musculoskeletal focused a
value. and expertise leaves innovation to positioned drive products us and Our space this well in create of portfolio
our implementation NOPAIN. commercial the for utilization access In the lay we initiatives market advance groundwork foundation of and modernized as best expanded for parallel, of Third, the continue we've powerhouse. medical to we established a EXPAREL practice commercial ahead
As reimbursement X% you XXXX. policy important begin will plus ASP separate outpatient this in reimbursement know, providing at
another around awareness among its on growing of and to and potential C-suite findings, understanding patient decision-makers and our Similar market among round We've original NOPAIN care and completed impact hospital hospital key these key stakeholders. research is stakeholders.
reimbursement expect We organizations. new time take to this across it customers implement will for their
pleased XXXX. also that of report will own J-code to its product-specific We're EXPAREL beginning in have January
combined coding J-code types commercial addition and more In by to and to the reimbursement sites different and from expanding NOPAIN, particularly likely is covered billing payers. reimbursement with This, is process, care a access be of impending recognized streamlining to payers. across EXPAREL of important
care use As be pricing we're broaden to management. can health you also the the at these pave partnering systems to and with programs, opportunity Through preferential NOPAIN. for know, of the afford forefront way GPOs pain opioid-sparing
early of will launched be XX% go on end or EXPAREL recently next new agreement Once covers another GPO partnership year. whose for relevant with track completed, Vizient a the live our and network of partnership We of XX% this We're cover procedures. of final third to will market. the more under EXPAREL at market This business than XX% significant contract. year approximately
performing to according quarter with ZILRETTA iovera°. products Both and are sales. third Turning to solid plan
results market a steroid with in each Shoulder study long-acting only ZILRETTA sizable the first could Our progressing OA year. expected this OA ZILRETTA XXXX. for injections registrational for shoulder use make line study successful, X Phase million opportunity intra-articular III represents approximately If is in administered in with approved top shoulders. and
CMS pleased for C-XXXX. rule ASC product-specific includes separate prospective qualifies concluded newly ASC statutory final hospital see both requirements their the final meet and system payment for that on iovera°, NOPAIN We're for iovera°, XXXX. iovera° created a code reimbursement for rule, in hospital of the As settings. issued to and rule Friday, and the that CMS In outpatient its
procedural rule and to sites add-on the the iovera° addition adopts hospital in Importantly, a consistent rates ASC payment $XXX of to care. up outpatient standard the of in
study Our for treatment iovera° also with is in results spasticity underway expected line for registrational the of XXXX. top
for the unmet severe of lack moderate may significant seeking innovation treatment. who a Given in this condition, novel to iovera° patient offer we spasticity and debilitating need are believe with approach patients
smart year. opioid is for use use. preparing tip team poor leads to quality is life, often This a specifically impacts chronic tip of millions also iovera° for of in low disability, this iovera° file The and approval Americans pain, to of which new designed later prescription back and
gears our pipeline. earlier-stage to Switching
to continue the and our challenges treatment PCRX-XXX, knee. of HCAD innovative therapy novel local of solve design, by process for encouraged that high-capacity have the of We adenovirus gene diseases. be for manufacturing common osteoarthritis or the many inaccessible gene Its the for potential therapy of administration made
following: the cost injected the leading is goods medicine into is scalable and clinical result vector profile. robust administration capsule safety more This it local genes effect PCRX-XXX of to HCAD efficient into than delivering joint a locally favorable manufacturing knee vectors. matters. the Smaller and delivering profile. at Key is other to It's less means there, medication in an and the doses, contained cells attributes XXX effect. desired viral include where needed of achieve attractive
exceeded with early-stage intra-articular pain single demonstrated I expectations durability disease by Phase In of injection severity trial. severe of levels as in across OA, clinical to large already WOMAC moderate PCRX-XXX a relief and this scores. XX PCRX-XXX has measured of knee all study an the patients
doses co-administered a a Earlier X-year data. with we in this at pain with meaningful. presented year, a receive all XX% greatest clinically The observed X doses. efficacy in all steroid and X improvement achieving patients baseline A improvement pretreated stiffness steroid. is group tolerated was the least PCRX-XXX XX% enrolled was efficacy and versus XX% observed studied. for well not considered of across cohort, steroid study cohort did The cohorts, that X-dose
are highly So these results encouraging.
data to X-year College new Rheumatology's and We Meeting American of continue look at exciting week. reporting these next Annual the forward to follow patients
more While gene with achieve results PCRX-XXX FDA's standard a relief months, the set first OA X year a testament pain typically therapy is and injection. designation, earn potential the for provide new from other to X of single or OA. PCRX-XXX relief its a therapies sustained gene a these already to the and the promise of to therapy RMAT only to knee to revolutionize has treatment
the at and of asset. we to perimeter to an section learn educational available this Investors a website. presentation webinar We exciting our in invite As watch you ACR, about PCRX-XXX more made
on patent litigation. touch is XXX closing I'll quickly before recent the last item The on ruling District Court's our
outcome was, the for, it course, is the of we this had not only that case. hoped to important this first remember While was
respect legal accordingly. an is pursuing through at to injunction Our this the harm at-risk strategy information changes, legal appellate received to time. imminent review adjust not an we're an includes court comprehensive with based on If prepared launch irreparable proceedings, this from we ongoing is and strategy believe do our
believe a to commercially of will in overcome we successful, As have all need EVS order our reminder, to be patents.
hurdle to the that's trial which defendants forthcoming. This innovate XXX for involves Importantly, lawsuit Court. the to are team second a patent, the additional We're date clear. in our case higher represents Jersey for District New also waiting we believe a continues progressing and patents
lacking claims XXX composition but XXX in case. the EXPAREL volume judge includes The patent found of the the limitation
to stakeholders. business, patients multiple take the We protect strong that interest of other a and to the firmly built intellectual believe levels. the steps our shareholders, portfolio well will property necessary EXPAREL on franchise We of is and continue we've protected
banker. with welcome our to turn formally biotechnology as of the strategies like financials plan is provide as over, I'm than he'll for more we Shawn of Cross. a Shawn new industry advance insights growth value and years I'd veteran confident valuable call executive, global a Board I seasoned XX Before member great Officer, and investment Financial steward long-term Chief and experience a and And creation. our be our
our thank I'm ongoing Vice been to has which she and President during of XX our years, this acumen. as demonstrated who I'd Finance, exceptional and like dedication during financial accept served Interim time grateful to has Lauren responsibility to for Senior Lauren Riker, for Pacira willingness period. leadership CFO. transitional this with Lauren
over that, for turn I'll of financials. call our to the Shawn review With a
